Aortic Arch, Aortic Diseases, Aortic Root Dilatation, Aortic Root Dissection, Aortic Valve Insufficiency, Ascending Aortic Dissection, Type A Aortic Dissection, Type B Aortic Dissection
Conditions
Keywords
DeBakey type I Dissection, DeBakey type II Dissection, Type A Acute Aortic Dissection (TAAAD), Root-Sparing Replacement, Ascending Aorta Replacement, Partial Arch Repair, Hemiarch Procedures, Total Arch Replacement (TARP), Frozen Elephant Trunk (FET) Hemiarch Procedures, Type B Acute Aortic Dissection (TBAAD), Type B non acuteAortic Dissection (TBAD)
Brief summary
Type A aortic dissection (TAAD) is a potentially life-threatening pathology associated with significant risk of mortality and morbidity. In acute forms of type A aortic dissection (TAAD) mortality is 50% by 24 h and 50% of patients die before reaching a specialist center. Rapid diagnosis and subsequent prompt surgical repair remain the primary goal for these patients. In the last decade it has been observed that improvements in diagnostic techniques, initial management and increased clinical awareness have contributed to a substantial increase in the number of patients benefiting from a prompt diagnosis and undergoing surgery.However, survival after surgical repair has not yet reached optimal follow-ups and is burdened by high in-hospital mortality(16-18%)The main approach to acute type B non-complicated aortic dissection (TBAD) has always been to use medicines to control the patient's heart rate and blood pressure. However, recent findings suggest that a large number of patients treated for acute complicated (TBAAD) and non-complicated TBAD experience aortic complications, such as aneurysmal degeneration, at a later stage.
Detailed description
For patients requiring surgical repair for a TAAD, there is still some disagreement regarding which factors should be considered during the preoperative evaluation, the best decision-making process to undertake that best assesses procedural risk, and how operative mortality can be predicted. Furthermore, the impact of different surgical strategies on outcomes remains unclear.This prospective study was designed to evaluate the impact of the center volume-outcome relationship and that on mortality which remain poorly understood. A better understanding of the determinants of outcome in patients undergoing surgery could support decision making, aid in the design of service delivery, and improve outcomes for surviving patients who are referred to specialized centers for treatment of aortic disease.Furthermore, the study aims to evaluate whether precise risk stratification can provide better patient counseling and be used for unit-surgeon benchmarking. Ultimately in the present study, we aimed to investigate outcome predictors in patients undergoing surgery for TAAD, including clinical and perioperative variables as well as to evaluate follow up beyond 15 years.TBAD occurring beyond the left subclavian artery (LSA) is classified in chronological order based on the timing of clinical presentation: acute (14 days or less), subacute (more than 14 days and less than or equal to 3 months), and chronic (more than 3 months).TBADs are also divided into complicated or non-complicated based on their initial clinical manifestation. Acute complicated TBAD is characterised by tearing of the aorta, pain, rapid expansion, hypertension, or blockages in the vasculature.Malperfusion syndrome is the most common complication, occurring in nearly 30% of cases. More than 30% of patients with mesenteric compromise following aortic dissection die .
Interventions
PROCEDUREConservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair
Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
PROCEDUREExtensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)
Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
PROCEDUREExtensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)
Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
PROCEDUREExtensive Root and Ascending Aorta Replacement with Total Arch Replacement
This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
PROCEDUREThoracic Endovascular Aortic Repair
TEVAR patients have a higher incidence of complications and reintervention than open repair patients. TEVAR complications may include endoleak, retrograde type A aortic dissection, stent-graft migration, fracture or collapse, and increased size.
PROCEDUREOpen Thoracic Aortic Descendig Repair
Surveillance imaging can detect complications of open repair, such as graft infection and anastomotic pseudoaneurysm. After open repair or TEVAR, patients may develop progressive aneurysmal dilatation of adjacent or remote aortic segments.
Sponsors
Centre Cardiologique du Nord
Henri Mondor University Hospital
Universita degli Studi di Genova
Pitié-Salpêtrière Hospital
Ospedale San Camillo, Rome, Italy
Campus Bio-Medico University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged \> 18 years * TAAD or intramural hematoma involving the ascending aorta * Symptoms started within 7 days from surgery * Primary surgical repair of acute TAAD * Any other major cardiac surgical procedure concomitant with surgery for TAAD.
Exclusion criteria
* Patients aged \< 18 years * Onset of symptoms \> 7 days from surgery * Prior procedure for TAAD * Concomitant endocarditis; * TAAD secondary to blunt or penetrating chest trauma.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Operative Mortality (OM) | 30-day | Patients who died within 30 days |
| Rate of mesenteric ischemia | 30-day | Rate of abdominal pain with or without nausea and vomiting and rectal bleeding or bloody diarrhea |
| Rate of permanent Neurologic Deficit (PND) | 30-day | Number of participants with acute episode of a focal or global neurological deficit. Rates of alteration of degree of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopsia, amaurosis fugax. To consider rate of other neurologic signs or symptoms consistent with stroke duration of focal or global neurologic deficit greater than 24 hours. |
| Rate of composite of Major Adverse Events (MAE) | 30-day | Number of participants with MAE which will include the composite rate of myocardial infarction, cerebrovascular accident, need for dialysis, or need for tracheostomy according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) |
| Rate of perioperative Myocardial Infarction (MI) | 30-day | Number of participants with MI based on fourth universal definition. |
| Rate of acute heart failure (AHF) | 30-day and in-hospital mortality | Number of participants with postoperative AHF who will require prolonged use of concentration of inotropes for a period greater than 24 h and/or the insertion of any mechanical circulatory support device. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Transient Neurologic Deficit (TND) | 30-day | Number of participants who will complicate postoperatively with episode of TND which will include complication rate such as confusion, delirium, agitation |
| Rate of spinal Cord Injury (SCI) | 30-day | Number of participants with SCI intended as rate of paraplegia and/or paraparesis |
| Rate of acute kidney injury | 30-day | Number of participants with postoperative change in serum creatinine concentration. Severity will be stratified on the basis of number of participants with the KDIGO (Kney Disease Improving Global Outcomes) criteria. |
| Rate of perioperative bleeding | 30-day | Number of participants who will receive postoperative transfused red blood cell units. The E-CABG ( coronary artery by pass grafting) classification of bleeding rate has been proposed as a simple classification of perioperative bleeding |
| Reoperation for bleeding | 30-day | Number of participants who will receive postoperative chest reopening for excessive bleeding. |
| Rate of mechanical circulatory support | 30-day | Number of participants who will receive the use of intra-aortic balloon pump and/or venoarterial extracorporeal membrane oxygenation for postoperative acute heart failure. |
| Rate of composite of Major Adverse Pulmonary Events (MAPE) | 30-day | Number of participants with MAPE which will include the composite rate of intubation \>48 hours, pneumonia, reintubation, tracheostomy according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) |
| Rate of reintervention | 18-years | The number of participants who will require reoperation for the aortic valve, proximal aorta, or distal aorta. |
| Rate of late survival | 18-years | Data on patient's survival status will be collected |
Countries
France
Contacts
STUDY_CHAIRFrancesco Nappi, MD
Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis, Paris, France
Outcome results
None listed